

Sufficient materials are included in the kit to allow the separation of CD3<sup>+</sup> T cells from approximately 2.4 x 10<sup>8</sup> peripheral blood mononuclear cells (PBMC). The maximum number of PBMC employed per separation in the FerroSelect™ QP5 Quadrupole magnet is 8.0 x 10<sup>7</sup> cells.

### **Product Description:**

1.0 mL of 12 µg/mL biotinylated monoclonal antibody (mAb) in PBS containing 1.0% recombinant human serum albumin (rHSA).

1.0 mL of 75 µg/mL streptavidin ferrofluid (SA-FF) in 0.3% rHSA.

Storage: Store at 2 – 8 °C. **Do Not Freeze.**

Expiry Date as per label/CoA (contact [quality@biomagneticsolutions.com](mailto:quality@biomagneticsolutions.com) for updates).

### **Product Applications:**

Negative selection of CD3<sup>+</sup> cells from apheresis products, PBMC, or cell culture suspensions. The isolated cells can be used for further analysis, assays, and expansion studies.

BioMagnetic Solutions have used fresh (non-frozen) cellular products for method development. Customers using frozen products such as cord blood for cell selection studies should develop their own procedures.

### **Additional Recommended Materials:**

The items below are used to produce the buffer employed in the negative selection of CD3<sup>+</sup> cells: Phosphate Buffered Saline containing 1.0% HSA (PBS-HSA).

- Phosphate buffered saline supplied separately by BioMagnetic Solutions (Cat. No: 14-0006, 14-0008).
- Human Serum Albumin (25% HSA, Akron, Cat. No: AK8228-0100 or equivalent depending upon end user requirements).

Cellular products employed in the negative selection of CD3<sup>+</sup> cells should be washed (as necessary) and resuspended in the above buffer at a concentration of 2.0 x 10<sup>8</sup> cells/mL.

5 mL tube to be used with the QP5 quadrupole (12 x 75 mm tube).

FerroSelect™ QP5 Quadrupole Magnet – Cat. No: 24-0001

### **Safety:**

Wear gloves, a lab coat, and safety glasses at all times when handling reagents and blood products.

Cells selected using the RUO reagent kit are **not** for human use.

Users have a 'duty of care' to dispose of all biological waste safely in accordance with biomedical waste guidelines.

### **Warranty:**

BioMagnetic Solutions does not offer any warranty regarding the performance of the reagent kit due to the variability of the starting product employed for cell selections.

The kit should not be used after its expiry dating.

## Procedure

The following procedure was developed by BioMagnetic Solutions' Research and Development Department as a guide to the end user. Approximately  $8.0 \times 10^7$  PBMC were employed as the starting product per the experiment described below, and the cell separations were undertaken using a 5 mL (12 x 75 mm) tube fitting into the FerroSelect™ QP5 Quadrupole magnet.

### 1. Cell Preparation

The starting cellular product may be washed and resuspended in PBS-HSA (buffer) to a concentration of  $2.0 \times 10^8$  cells/mL (0.4 mL) using a 5 mL tube. NOTE: BioMagnetic Solutions' data shows that the product does not need to be washed prior to antibody labeling, but the product may be washed as required by the end user.

### 2. Antibody Labeling

Approximately 266  $\mu$ L of buffer should be added to the cell mixture before adding the biotinylated mAb.

The vial of biotinylated mAb should be gently mixed and 134  $\mu$ L of antibody added to the tube containing the cells. The tube's contents should be mixed gently by pipetting. The incubation volume will be 0.80 mL.

Cells should be incubated for 5 minutes at room temperature.

### 3. Ferrofluid Labeling

Approximately 480  $\mu$ L of buffer should be added to the tube before adding SA-FF.

The vial of streptavidin ferrofluid should be gently mixed by inversion and 320  $\mu$ L of SA-FF added to the cell suspension **without** washing excess mAb from the cellular product. The tube should be mixed gently by pipetting. The incubation volume will now be 1.6 mL.

Cells should be incubated for 5 minutes at room temperature.

### 4. Cell Separation

After incubation, 2.4 mL of buffer should be added to the tube containing the cell suspension and gently mixed.

The tube should be inserted into the quadrupole magnet with a separation time of 10 minutes to allow cells labeled with SA-FF to be drawn to the walls of the tube.

The supernatant should be carefully aspirated with a Pasteur pipette from the tube without touching the tube's sides.

The collected supernatant is the fraction containing untouched CD3<sup>+</sup> T Cells.

### 5. Expected Results

BioMagnetic Solutions have used this protocol to obtain a mean purity of CD3<sup>+</sup> cells of 88.5% and a mean yield of 64.5% (datasheets available on request), although the end user should be aware that variations in the starting product will impact the results obtained.